Feature | January 03, 2017| Anamika Kumari

Capsule Endoscopy Systems Safety in Patients With Cardiovascular Implants

Given, Pillcamp, colonoscopy, Angiodysplasias, capsule Endoscopy, LVAD interference

The Given Imaging PillCam Colon system is an example of a capsule endoscopy device the patient swallows to image the gastrointestinal track.

The capsule endoscopy systems offer a hands-free and highly accurate imaging modality for healthcare practitioners. A pill-sized capsule houses a miniature camera that captures the condition of esophageal tract lining. The technology was first introduced for commercial healthcare services in 2000. These capsule devices are now being used to help assess gastrointestinal issues related to cardiovascular devices. 

Gastrointestinal bleeding is a common side effect in patients who have a left-ventricular assist device (LVAD). Angiodysplasias, or vascular ectesias, is another form of varices in the lower colon that is closely associated with the presence of complex cardiovascular therapeutic devices. Angiodysplasias can be further aggravated with the use of anticoagulants commonly used in patients with LVADs and with some cardiovascular conditions.

The U.S. Food and Drug Administration (FDA) identifies the generic capsule endoscopic device as a prescription, single-use ingestible capsule designed to acquire video images during natural propulsion through the digestive system. Recently, the use of capsule endoscopy was contraindicated for patients with cardiac implants, because of the possibility of interference during in vivo functions of both the class of devices. 

However, there is enough evidence-based research to nullify this concern. A team from the Division of Gastroenterology and Hepatology and Division of Cardiology, Mayo Clinic Arizona, found capsule endoscopy is safe in patients with implanted cardiac devices.[1] They found PillCam’s maximum transmission power is below the permitted limits for cardiac devices, so there should not be any impairment of pacemakers, implantable cardioverter defibrillators (ICD) or LVADs. However, the study found wireless telemetry can cause dysfunction of capsule endoscopy recording. 

The study looked at five patients referred to capsule endoscopy with the indication of gastrointestinal bleeding of obscure origin were included in the study. A cardiologist, assisted by an expert nurse, observed the functions of the pacemaker before and after the capsule transmission. As per their report, no adverse effects were observed on cardiovascular activities resulting from the procedure. The research team concluded that there were issues with the function of either device.[1] 
Additional Mayo Clinic study found capsule endoscopy systems do not interfere with implantable electronic devices (IEDs) function.[2] The study found capsule endoscopy did not interfere with IED function, including pacemakers, ICDs or LVADs, and pacemakers and ICDs did not interfere with the capsule imaging. However, they found LVADs might interfere with capsule images and require that capsule leads be positioned as far away as possible from the IED to assure reliable image acquisition.

While experts continue to connect the dots between angiodysplasias and cardiovascular disorders to establish indications for increased bleeding risks in patients. A study on the same topic was presented by Stephanie Mai, M.D., Loma Linda University Medical Center, Calif., at the Digestive Disease Week conference in 2016.[3] The study found there is an increased need for blood transfusions in patients with both implanted cardiovascular devices and angiodysplasias. 

The study included 87 patients who had small bowel gastrointestinal angiodysplasias. Of that group, 48 had vascular disorders, leading to a six-fold increase risk of requiring blood transfusions.
Mai was also involved in another study that found peripheral vascular disease was significantly associated with non-isolated gastrointestinal angiodysplasia.[4]

Barring capsule endoscopy system from being employed for diagnostic imaging in CVD patients will only complicate the imaging procedure. There is already clinical evidence establishing a higher probability of people with cardiovascular implants to develop colon issues. In the absence of enough evidence showing the imaging procedure has any adverse effect on cardiovascular implants, healthcare professionals are not ready to discontinue the use of practice of capsule endoscopy. 

The capsule endoscopy system market offers single-use disposable products that do not require surgical procedures or the administration of anesthesia. There are various products developed by the manufacturers in this segment, customized to function in the different parts of the gastrointestinal tract. For instance, PillCam is a range of capsule endoscopic devices manufactured by Given Imaging Ltd., including PillCam SB, PillCam Colon and PillCam ESO. 

The PillCam Colon 2 was recently approved by FDA for use in diagnostic imaging in the presence of suspected lower colon bleeding. The clearance will pave way for easy detection of colon polyps in suspected cases. 

Product developers of capsule endoscopy systems have made remarkable progress in terms of innovative hardware and software technologies. Despite the obvious challenges, they have been successful in maintaining adherence to safety standards. While some novice products await clearance from regional drug and device regulating authorities, most of them have already had a positive influence on millions of lives and resulted in better patient outcomes. 

For more information: www.alliedmarketresearch.com/capsule-endoscopy-system-market

Editor’s note: Anamika Kumari is a content writer for Allied Analytics LLP. She has a bachelor’s degree in electrical engineering and is certified in industrial automation. 

References:

1. Dirk Bandorski, Reinhard Höltgen, Dominik Stunder, et al. “Capsule endoscopy in patients with cardiac pacemakers, implantable cardioverter defibrillators and left heart assist devices.” Ann Gastroenterol. 2014; 27(1): 3–8.

2. Lucinda A. Harris, Stephanie L. Hansel, Elizabeth Rajan, et al. “Capsule Endoscopy in Patients with Implantable Electromedical Devices is Safe.” Gastroenterol Res Pract. 2013; 2013: 959234. Published online 2013 Apr 3. doi:  10.1155/2013/959234

3. Stephanie Mai. “Transfusion Rates Are Higher in Patients With Small Bowel Gastrointestinal Angiodysplasias Who Present With Melena and Vascular Disease.” May 21, 2016 presentation at Digestive Disease Week conference. Abstract Su1062.

4. Stephanie H. Mai, Christian S. Jackson, Michael D. Baek. “Su1061 Peripheral Vascular Disease Is Significantly Associated With Non-Isolated Gastrointestinal Angiodysplasia.” GIE, May 2016, Vol. 83, Issue 5, Supplement, Pages AB314–AB315DOI: http://dx.doi.org/10.1016/j.gie.2016.03.801.

Related Content

New Multimodality Cardiac Imaging Guidelines for Competitive Athletes Created. ASE SCCT and SCMR recommendations for imaging, screening atheletes.
News | Cardiac Imaging | May 11, 2020
May 11, 2020 – Competitive athletes are a rapidly growing population worldwide.
Figure 4 for the study. Images of a 65-year-old man (patient 6). (a) Cardiac MRI perfusion shows perfusion deficit of anterior/anterolateral wall attributed to left anterior descending artery/left circumflex artery (*). (b) CT coronary angiography. (c) Coronary angiography, left anterior oblique projection with caudal angulation. (d) Three-dimensional image fusion helped refine diagnosis: perfusion deficits (*) were most likely caused by narrow first diagonal branch and its first, stented side branch (arrow

Figure 4 for the study. Images of a 65-year-old man (patient 6). (a) Cardiac MRI perfusion shows perfusion deficit of anterior/anterolateral wall attributed to left anterior descending artery/left circumflex artery (*). (b) CT coronary angiography. (c) Coronary angiography, left anterior oblique projection with caudal angulation. (d) Three-dimensional image fusion helped refine diagnosis: perfusion deficits (*) were most likely caused by narrow first diagonal branch and its first, stented side branch (arrowhead). Retrospectively, denoted lesion could also be found at CT coronary angiography and coronary angiography (arrowheads in b and c, respectively). CT FFR = CT-derived fractional flow reserve, LGE = late gadolinium enhancement. Image courtesy of RSNA, Radiology.

News | Cardiac Imaging | May 04, 2020
May 4, 2020 – A new technique that combines computed tomography (CT) and magnetic resonance imaging MRI can bolster c
An example of a coronary computed tomography angiography (CCTA) exam. The CIAO study looked at patients who have a problem of blood flow limitation and chest pain symptoms in the absence of a 50 percent or more artery narrowing, known as ischemia with no obstructive CAD, or INOCA.

An example of a coronary computed tomography angiography (CCTA) exam. The CIAO study looked at patients who have a problem of blood flow limitation and chest pain symptoms in the absence of a 50 percent or more artery narrowing, known as ischemia with no obstructive CAD, or INOCA.

News | Cardiac Imaging | April 03, 2020
April 3, 2020 — Patients who experience chest pain and have abnormal results on a cardiac stress test but who do not
Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data

Figure 1: Depiction of the fully automated CT biomarkers tools used in this study. (A) Schematic depiction of the automated process for assessing fat, muscle, liver, aortic calcification, and bone from original abdominal CT scan data. (B) Case example in an asymptomatic 52-year-old man undergoing CT for colorectal cancer screening. At the time of CT screening, he had a body-mass index of 27·3 and Framingham risk score of 5% (low risk). However, several CT-based metabolic markers were indicative of underlying disease. Multivariate Cox model prediction based on these three CT-based results put the risk of cardiovascular event at 19% within 2 years, at 40% within 5 years, and at 67% within 10 years, and the risk of death at 4% within 2 years, 11% within 5 years, and 27% within 10 years. At longitudinal clinical follow-up, the patient suffered an acute myocardial infarction 3 years after this initial CT and died 12 years after CT at the age of 64 years. (C) Contrast-enhanced CT performed 7 months before death for minor trauma was interpreted as negative but does show significant progression of vascular calcification, visceral fat, and hepatic steatosis. HU=Hounsfield units.

News | Cardiac Imaging | March 06, 2020
March 6, 2020 — Researchers at the National Institutes of Health a
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along with eight other...
Philips Debuts Cardiac Ultrasound and Enterprise Informatics Offerings at ESC 2019
News | Cardiac Imaging | August 30, 2019
Philips will showcase its latest cardiac care innovations at the European Society of Cardiology (ESC) Congress 2019,...